Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women with breast cancer who are between 18 and 75 years old
• People whose overall health and ability to carry out daily activities meets a standard rating of 0 or 1 on a commonly used medical scale (meaning generally active and able to care for themselves)
• People whose breast cancer has been confirmed through a tissue or cell sample to be advanced triple-negative breast cancer (a type of breast cancer that lacks three common receptors)
• People who have not yet received any systemic treatment — such as chemotherapy, targeted therapy, or immunotherapy — for their advanced triple-negative breast cancer
• People who have at least one tumour that can be measured using standard imaging criteria
• People who have decided to receive treatment with the combination of sacituzumab govitecan and toripalimab (the two drugs being studied in this trial)

Who may not be able to join:

• People who have brain metastases (cancer that has spread to the brain) causing active symptoms — such as increased pressure in the skull or seizures — that require urgent radiation therapy or surgery
• People who have previously received therapies specifically targeting HER2 or a protein called Trop-2
• People who have previously used or are currently using certain types of immune checkpoint drugs (called PD-(L)1 inhibitors), or certain types of antibody-drug combinations or medicines that affect an enzyme called topoisomerase — including drugs such as sacituzumab govitecan or Dato-DXd (confirm with trial site)
• People whom the trial investigator considers unsuitable for participating in this study for any reason

Important: Always verify eligibility with the trial site directly before applying.